GO:0034418 urate biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034418 (urate biosynthetic process) describes the biochemical reactions that produce urate, the anion of uric acid, from purine precursors.
• Urate is the final product of purine catabolism in humans because the gene encoding urate oxidase (UOX) is non-functional.
• The process is tightly linked to renal and extra-renal urate transport systems that determine serum urate levels.
• Dysregulation of urate production and excretion contributes to hyperuricemia, gout, and cardiometabolic disease.
• Emerging evidence links elevated urate to erectile dysfunction through interaction with MLCK and inhibition of its ubiquitin-mediated degradation.
• CRISPR-based models (knockout, knock-in, overexpression) enable causal dissection of genes in the urate biosynthetic pathway.
Description
Urate biosynthetic process (GO:0034418) is defined as the chemical reactions and pathways resulting in the formation of urate, the anion of uric acid (2,6,8-trioxypurine). In humans, urate is the end product of purine metabolism because the enzyme urate oxidase (UOX) is non-functional, making urate the terminal purine catabolite. This process is central to nitrogen metabolism and redox balance, and its dysregulation is a major driver of hyperuricemia and gout. Understanding the genes and regulatory steps of urate biosynthesis is therefore critical for both basic biochemistry and clinical translation. Recent studies have also implicated urate in broader physiological and pathological contexts, including erectile dysfunction and metabolic syndrome. This article synthesizes authoritative GO annotation and verified literature to provide a research-grade overview of GO:0034418, its genes, regulation, disease links, and experimental models.
urate biosynthetic process At A Glance
| GO ID | GO:0034418 |
|---|---|
| GO term | urate biosynthetic process |
| Ontology | biological_process |
| Synonym | urate anabolism; urate biosynthesis; urate formation; urate synthesis; uric acid biosynthetic process |
| Major function | Production of urate (uric acid anion) from purine precursors |
| Key enzymes | Xanthine oxidase (XDH), xanthine dehydrogenase, purine nucleoside phosphorylase (PNP), hypoxanthine-guanine phosphoribosyltransferase (HPRT1) |
| Key transporters | URAT1 (SLC22A12), GLUT9 (SLC2A9), ABCG2, OAT1, OAT3 |
| Related diseases | Hyperuricemia, gout, renal hypouricemia, metabolic syndrome |
| Research relevance | Target for urate-lowering therapies and CRISPR-based functional genomics |
What Is GO:0034418?
GO:0034418 (urate biosynthetic process) encompasses the enzymatic steps that convert purine derivatives into urate, the anionic form of uric acid. It includes both de novo purine synthesis and salvage pathways that feed into urate production, as well as the terminal oxidation steps that generate urate. The term is synonymous with urate anabolism, urate biosynthesis, urate formation, urate synthesis, and uric acid biosynthetic process.
Why Is urate biosynthetic process Important in Cell Biology?
Urate biosynthetic process is important because it determines systemic urate levels, which are directly linked to hyperuricemia, gout, and cardiovascular risk. The balance between urate production and excretion is a major determinant of serum urate, and genetic variants in urate transporters and enzymes influence this balance. Moreover, urate has antioxidant properties at physiological concentrations but can become pro-oxidant and pro-inflammatory when elevated. Understanding GO:0034418 therefore informs therapeutic strategies for gout and related metabolic disorders.
• Urate is the final product of purine catabolism in humans due to loss of urate oxidase activity.
• Altered urate biosynthesis contributes to hyperuricemia and gout.
• Renal and extra-renal urate transport determines serum urate levels.
• Genetic variants in urate transporters such as SLC22A12 and SLC2A9 cause renal hypouricemia or hyperuricemia.
• Urate can modulate oxidative stress and inflammation.
• Elevated uric acid is associated with erectile dysfunction via MLCK interaction.
• Gut microbiome and metabolome reprogramming can ameliorate hyperuricemia.
• Urate biosynthetic enzymes are potential drug targets for urate-lowering therapy.
• CRISPR screens can identify novel regulators of urate production.
• Modeling urate biosynthesis in cells enables mechanistic studies of purine metabolism.
What Happens During urate biosynthetic process?
Purine nucleotide catabolism to hypoxanthine
In simple terms: Purines from DNA/RNA and diet are broken down step by step into hypoxanthine.
The urate biosynthetic process begins with the degradation of purine nucleotides (AMP, GMP, IMP) to nucleosides and then to hypoxanthine. Key enzymes include purine nucleoside phosphorylase (PNP) and xanthine dehydrogenase (XDH). This step is regulated by the availability of purine substrates and the activity of salvage enzymes such as HPRT1.
Oxidation of hypoxanthine to xanthine
In simple terms: Hypoxanthine is converted to xanthine by xanthine oxidase.
Hypoxanthine is oxidized to xanthine by xanthine oxidase (XO) or xanthine dehydrogenase (XDH). This reaction generates hydrogen peroxide and is a major source of reactive oxygen species during urate production. The enzyme XDH is a critical node in GO:0034418 and is targeted by allopurinol and febuxostat.
Oxidation of xanthine to urate
In simple terms: Xanthine is converted to urate, the final product.
Xanthine is further oxidized to urate by xanthine oxidase. In humans, urate cannot be further degraded because urate oxidase (UOX) is non-functional, making urate the terminal product. This step is the defining reaction of GO:0034418 and is directly measured in biochemical assays.
Transport and excretion of urate
In simple terms: Urate is moved out of cells and into blood, then excreted by kidneys and gut.
Once formed, urate is transported across cell membranes by urate transporters including URAT1 (SLC22A12), GLUT9 (SLC2A9), and ABCG2. Renal and extra-renal excretion determines serum urate levels. Dysfunction of these transporters leads to hyperuricemia or hypouricemia.
Regulation by metabolic and hormonal signals
In simple terms: The process is tuned by signals like insulin, inflammation, and gut metabolites.
Urate biosynthesis is influenced by metabolic status, including insulin resistance and inflammation. Gut microbiome metabolites can modulate urate levels, as shown by sulforaphane-driven reprogramming. Elevated uric acid can also interact with MLCK and inhibit its ubiquitin-mediated degradation, linking urate to erectile dysfunction.
Key Genes Involved in GO:0034418 urate biosynthetic process
The following genes and proteins are central to urate biosynthetic process (GO:0034418) and its regulation, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| XDH | Xanthine dehydrogenase/oxidase catalyzes hypoxanthine to xanthine and xanthine to urate | Target of allopurinol; key enzyme in urate production |
| PNP | Purine nucleoside phosphorylase converts inosine to hypoxanthine | Links purine salvage to urate synthesis |
| HPRT1 | Hypoxanthine-guanine phosphoribosyltransferase salvages hypoxanthine | Deficiency causes Lesch-Nyhan syndrome with hyperuricemia |
| SLC22A12 | URAT1 mediates renal urate reabsorption | Mutations cause renal hypouricemia |
| SLC2A9 | GLUT9 facilitates urate transport in kidney and gut | GWAS link to serum urate and gout |
| ABCG2 | ATP-binding cassette transporter exports urate in gut and kidney | Dysfunction causes hyperuricemia |
| SLC22A6 | OAT1 mediates renal urate secretion | Basolateral urate transport |
| SLC22A8 | OAT3 mediates renal urate secretion | Basolateral urate transport |
| UOX | Urate oxidase degrades urate in most mammals but is non-functional in humans | Explains human hyperuricemia |
| MLCK | Myosin light chain kinase interacts with uric acid | Linked to erectile dysfunction |
| IL1B | Interleukin-1 beta mediates urate crystal inflammation | Gout inflammation |
| NLRP3 | Inflammasome sensor activated by urate crystals | Gout and inflammation |
| TNF | Tumor necrosis factor promotes inflammation in hyperuricemia | Inflammatory response |
| SLC17A1 | NPT1 transports urate in kidney | Urate excretion |
| SLC17A3 | NPT4 transports urate in kidney | Urate excretion |
| PDZK1 | Scaffold protein for urate transporters | Regulates URAT1 and others |
How Is urate biosynthetic process Regulated?
Urate biosynthetic process is regulated at multiple levels. Enzymatic activity of XDH is modulated by transcriptional and post-translational mechanisms, including phosphorylation and proteolysis. Substrate availability from purine salvage and de novo synthesis influences flux through the pathway. Hormonal and metabolic signals such as insulin resistance and inflammation can alter urate production and excretion. Gut microbiome metabolites, including those derived from sulforaphane, can reprogram urate metabolism and ameliorate hyperuricemia. Additionally, urate itself can interact with signaling proteins such as MLCK, affecting its ubiquitin-mediated degradation.
urate biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| XDH | Hyperuricemia and gout | XDH knockout or point-mutation cell lines; urate measurement |
| SLC22A12 | Renal hypouricemia | URAT1 knockout HEK293 cells; urate transport assay |
| SLC2A9 | Hyperuricemia and gout | GLUT9 knockout or overexpression in renal cells |
| ABCG2 | Hyperuricemia and gout | ABCG2 knockout intestinal or renal cell models |
| MLCK | Erectile dysfunction | MLCK point-mutation or knockout in smooth muscle cells |
Hyperuricemia and Gout
Hyperuricemia results from increased urate production, decreased excretion, or both. Overactivity of XDH and impaired renal urate excretion are common mechanisms. Gout is caused by deposition of monosodium urate crystals in joints, triggering NLRP3 inflammasome activation and IL-1beta release. Genetic variants in SLC22A12, SLC2A9, and ABCG2 are associated with gout risk.
Renal Hypouricemia
Loss-of-function mutations in SLC22A12 (URAT1) or SLC2A9 (GLUT9) cause renal hypouricemia, characterized by excessive urate excretion and low serum urate. This condition can lead to exercise-induced acute kidney injury.
Metabolic and Cardiovascular Disease
Elevated urate is associated with metabolic syndrome, hypertension, and cardiovascular disease. Urate-lowering therapies may reduce cardiovascular risk, although causality remains under investigation.
Erectile Dysfunction
Recent evidence shows that elevated uric acid induces erectile dysfunction in rats by interacting with MLCK and inhibiting its ubiquitin-mediated degradation. This highlights a novel role for urate beyond gout and kidney disease.
From urate biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does XDH loss reduce urate production? | XDH knockout cell line (e.g., HepG2) with urate assay |
| Does a SLC22A12 variant impair urate transport? | Point-mutation knock-in of SLC22A12 in HEK293 cells |
| Does SLC2A9 overexpression alter urate levels? | SLC2A9 overexpression in renal epithelial cells |
| Can ABCG2 tagging reveal urate export dynamics? | Tagged knock-in of ABCG2 with fluorescent tag |
| Does MLCK ubiquitination affect urate-induced ED? | MLCK point-mutation (ubiquitination site) in rat smooth muscle cells |
| Which genes regulate urate biosynthesis? | CRISPR library screening in urate-producing cell models |
How to Study the urate biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for urate production | Identify novel regulators of GO:0034418 |
| Urate oxidase assay | Urate concentration | Measure urate in cell culture or serum |
| HPLC/MS metabolomics | Purine metabolites including urate | Profile pathway flux |
| Urate transport assay | Transport activity of URAT1/GLUT9 | Characterize transporter variants |
| Western blot | Protein expression of XDH, PNP, HPRT1 | Validate knockout or overexpression |
| qPCR | mRNA levels of urate-related genes | Assess transcriptional regulation |
| Immunofluorescence | Subcellular localization of transporters | Study membrane trafficking |
| Animal hyperuricemia model | Serum urate and tissue pathology | Test urate-lowering therapies |
CRISPR Knockout Screens
Genome-wide CRISPR knockout screens can identify genes that regulate urate production. Cells are transduced with a sgRNA library, selected, and urate levels measured to find enriched or depleted sgRNAs.
Metabolomics and Urate Quantification
Urate levels can be quantified using enzymatic assays, HPLC, or mass spectrometry. Metabolomic profiling of purine intermediates provides a detailed view of flux through GO:0034418.
Transport Assays
Urate transport activity of URAT1, GLUT9, and ABCG2 can be measured in Xenopus oocytes or mammalian cells using radiolabeled urate or fluorescent probes.
Animal Models
Rodent models, including UOX knockout mice, mimic human hyperuricemia and allow study of urate biosynthesis in vivo. These models are useful for testing urate-lowering drugs.
How CRISPR Can Be Used to Study GO:0034418 urate biosynthetic process
Knockout
CRISPR knockout of XDH, SLC22A12, or ABCG2 can abolish or reduce urate production and transport, providing causal evidence for their roles in GO:0034418. Knockout cell lines are also used to validate drug targets.
Point Mutation
Point mutations in SLC22A12 or SLC2A9 identified in patients can be introduced into cell lines to study their effects on urate transport and serum urate levels. This approach helps distinguish pathogenic variants from benign polymorphisms.
Knock-in
Knock-in of tagged versions of urate transporters (e.g., GFP-ABCG2) allows real-time imaging of urate export and trafficking. Knock-in of human UOX mutations can model human hyperuricemia in mice.
Overexpression
Overexpression of XDH or SLC2A9 in cell lines increases urate production or transport, enabling gain-of-function studies. Overexpression models are useful for screening urate-lowering compounds.
How EDITGENE Supports urate biosynthetic process Research
Researchers studying urate biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in urate production, transport, or regulation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for urate biosynthetic process research.
Frequently Asked Questions About urate biosynthetic process
What is urate biosynthetic process (GO:0034418)?
It is the set of biochemical reactions that produce urate, the anion of uric acid, from purine precursors.
What genes are involved in urate biosynthetic process?
Key genes include XDH, PNP, HPRT1, SLC22A12, SLC2A9, and ABCG2.
Why is urate biosynthetic process important?
It determines serum urate levels, which are linked to hyperuricemia, gout, and cardiovascular disease.
How is urate biosynthetic process regulated?
It is regulated by enzyme activity, substrate availability, hormones, and gut microbiome metabolites.
What diseases are associated with urate biosynthetic process?
Hyperuricemia, gout, renal hypouricemia, metabolic syndrome, and erectile dysfunction.
What is the role of XDH in urate biosynthesis?
XDH catalyzes the oxidation of hypoxanthine to xanthine and xanthine to urate.
How can CRISPR be used to study urate biosynthetic process?
CRISPR knockout, knock-in, point mutation, and overexpression models can dissect gene function in urate production and transport.
What cell models are used for urate research?
HEK293, HepG2, renal epithelial cells, and UOX knockout mouse models are commonly used.
What is the link between urate and erectile dysfunction?
Elevated uric acid interacts with MLCK and inhibits its ubiquitin-mediated degradation, contributing to erectile dysfunction in rats.
Can diet affect urate biosynthetic process?
Yes, gut microbiome and metabolome reprogramming by compounds like sulforaphane can ameliorate hyperuricemia.
Conclusion
Urate biosynthetic process (GO:0034418) is a fundamental metabolic pathway that produces urate, the end product of purine catabolism in humans. Its dysregulation underlies hyperuricemia, gout, and related metabolic disorders, making it a key target for therapeutic intervention. Advances in CRISPR-based models and metabolomics are accelerating the discovery of novel regulators and drug targets within this pathway. Continued research into GO:0034418 will deepen our understanding of urate biology and improve clinical management of urate-related diseases.
References
- 1. So A et al.. 2010. Uric acid transport and disease.. J Clin Invest 120(6):1791-9 PMID: 20516647
- 2. Wang R et al.. 2023. Sulforaphane-driven reprogramming of gut microbiome and metabolome ameliorates the progression of hyperuricemia.. J Adv Res 52:19-28 PMID: 36371056
- 3. Mount DB et al.. 2006. Renal urate transport.. Rheum Dis Clin North Am 32(2):313-31, vi PMID: 16716882
- 4. Ichida K et al.. 2012. Decreased extra-renal urate excretion is a common cause of hyperuricemia.. Nat Commun 3:764 PMID: 22473008
- 5. Hisatome I et al.. 1996. [Renal hypouricemia].. Nihon Rinsho 54(12):3337-42 PMID: 8976116
- 6. Anzai N et al.. 2011. Urate transporters: an evolving field.. Semin Nephrol 31(5):400-9 PMID: 22000646
- 7. Gliozzi M et al.. 2016. The treatment of hyperuricemia.. Int J Cardiol 213:23-7 PMID: 26320372
- 8. Shen G et al.. 2025. Elevated uric acid induces erectile dysfunction in rats by interacting with MLCK and inhibiting its ubiquitin-mediated degradation.. Commun Biol 8(1):1190 PMID: 40783594
